Furore after Indian police shoot gangster dead

1 / 3
Policemen stand guard next to an overturned vehicle after the gangster Vikas Dubey was shot dead by police, on a highway at Sachendi in Uttar Pradesh state on July 10, 2020. (AFP)
2 / 3
Policemen arrive at the scene to investigate after the gangster Vikas Dubey was shot dead by police, on a highway at Sachendi in Uttar Pradesh state on July 10, 2020. (AFP)
3 / 3
Police officers cordon the site where top criminal Vikas Dubey was killed near Kanpur, India, Friday, July 10, 2020. (AP)
Short Url
Updated 10 July 2020

Furore after Indian police shoot gangster dead

  • Officials said Dubey was shot as he tried to escape a police vehicle while being driven to his home city
  • Rights lawyers alleged that police killed Dubey to prevent him revealing his connections with powerful people

LUCKNOW: Indian police shot dead one of the country's most wanted gangsters on Friday just a day after his dramatic arrest, sparking accusations of a staged extrajudicial killing.
Officials said Vikas Dubey, detained for the killing of eight police officers, was shot as he tried to escape a police vehicle while being driven to his home city in the northern state of Uttar Pradesh.
Within hours of TV stations carrying images of his bloodstained body lying in a hospital, rights lawyers and activists alleged that police had killed Dubey to prevent him revealing his connections with powerful people.
"This is the most blatant case of extra-judicial killing. Dubey was a gangster terrorist who may have deserved to die. But (Uttar Pradesh) police have killed him to shut his mouth," Supreme Court lawyer Prashant Bhushan wrote on Twitter.
"Will we allow police to kill anyone without a court trial?" Utsav Bains, another Supreme Court lawyer, added.
Senior opposition Congress party leader Priyanka Gandhi said the people "protecting" Dubey were still free and called for a judicial probe into the killing.
Dubey, aged about 50, was accused of more than 60 murders, attempted murders and other crimes. He was said to have shot dead an Uttar Pradesh state minister inside a police station in 2001.
Despite those cases and his reputation for ruthlessness, Dubey has built considerable local political links over the past two decades.
On July 3, eight officers were gunned down when his gang staged an ambush on a police team aiming to arrest him.
A nationwide manhunt was launched, during which five of Dubey's associates -- including his bodyguard nephew -- were killed.
Police said he was tipped off about the deadly raid by local officers, some of whom have been arrested for leaking information to the gangster.
He finally gave himself up in a temple in Madhya Pradesh state on Thursday.
According to the police account, the car transporting him early Friday overturned on a wet road in neighbouring Uttar Pradesh and he tried to escape.
"Dubey has been killed in an exchange of fire after he snatched the pistol of our men and tried to flee after firing at them. Four of our men are also injured," Kanpur police inspector general Mohit Agarwal told reporters.
Uttar Pradesh chief minister Yogi Adityanath, a senior member of Prime Minister Narendra Modi's Bharatiya Janata Party, has publicly endorsed police killings as a "deterrent" to crime.
Yogi's government has pledged to root out crime from the state and his tenure has coincided with a surge in the number of criminals dying in police shootouts.
"Encounter killings" have a long history India and for decades shootouts were staged to bypass India's judicial system when police battled armed separatist movements in West Bengal, Punjab, Kashmir and elsewhere.
"History repeats," Nirjhari Sinha, a civil rights leader from western Gujarat state, wrote on Twitter in response to Dubey's death.
"Dead gangsters can't speak about their political patronage."
More recently, suspects accused of violent crimes have died in custody.
Last year, police in southern India shot dead four men accused in the horrific rape and murder of a 27-year-old woman.


US to pay over $1 bn for 100 mln doses of J&J’s potential COVID-19 vaccine

Updated 05 August 2020

US to pay over $1 bn for 100 mln doses of J&J’s potential COVID-19 vaccine

  • The latest contract equates to roughly $10 per vaccine dose produced by J&J
  • This is J&J’s first deal to supply its investigational vaccine to a country

WASHINGTON: The United States government will pay Johnson & Johnson over $1 billion for 100 million doses of its potential coronavirus vaccine, its latest such arrangement as the race to tame the pandemic intensifies, the drugmaker said on Wednesday.
It said it would deliver the vaccine to the Biomedical Advanced Research and Development Authority (BARDA) on a not-for-profit basis to be used after approval or emergency use authorization by the US Food and Drug Administration (FDA).
J&J has already received $1 billion in funding from the US government — BARDA agreed in March to provide that money for the company to build manufacturing capacity for more than 1 billion doses of the experimental vaccine.
The latest contract equates to roughly $10 per vaccine dose produced by J&J. Including the first $1 billion deal with the USgovernment, the price would be slightly higher than the $19.50 per dose that the United States is paying for the vaccine being developed by Pfizer Inc. and German biotech BioNTech SE.
The US government may also purchase an additional 200 million doses under a subsequent agreement. J&J did not disclose that deal’s value.
J&J plans to study a one- or two-dose regimen of the vaccine in parallel later this year. A single-shot regimen could allow more people to be vaccinated with the same number of doses and would sidestep issues around getting people to come back for their second dose.
This is J&J’s first deal to supply its investigational vaccine to a country. Talks are underway with the European Union, but no deal has yet been reached.
J&J’s investigational vaccine is currently being tested on healthy volunteers in the United States and Belgium in an early-stage study.
There are currently no approved vaccines for COVID-19. More than 20 are in clinical trials.